Hörmann, A.A.; Klingler, M.; Rangger, C.; Mair, C.; Decristoforo, C.; Uprimny, C.; Virgolini, I.J.; von Guggenberg, E.
Radiopharmaceutical Formulation and Preclinical Testing of 68Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial. Pharmaceuticals 2021, 14, 575.
https://doi.org/10.3390/ph14060575
AMA Style
Hörmann AA, Klingler M, Rangger C, Mair C, Decristoforo C, Uprimny C, Virgolini IJ, von Guggenberg E.
Radiopharmaceutical Formulation and Preclinical Testing of 68Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial. Pharmaceuticals. 2021; 14(6):575.
https://doi.org/10.3390/ph14060575
Chicago/Turabian Style
Hörmann, Anton A., Maximilian Klingler, Christine Rangger, Christian Mair, Clemens Decristoforo, Christian Uprimny, Irene J. Virgolini, and Elisabeth von Guggenberg.
2021. "Radiopharmaceutical Formulation and Preclinical Testing of 68Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial" Pharmaceuticals 14, no. 6: 575.
https://doi.org/10.3390/ph14060575
APA Style
Hörmann, A. A., Klingler, M., Rangger, C., Mair, C., Decristoforo, C., Uprimny, C., Virgolini, I. J., & von Guggenberg, E.
(2021). Radiopharmaceutical Formulation and Preclinical Testing of 68Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial. Pharmaceuticals, 14(6), 575.
https://doi.org/10.3390/ph14060575
